Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma

Published:2011-11 Issue:11 Volume:6 Page:1889-1894
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nishio Makoto,Yamanaka Takeharu,Matsumoto Kazuko,Kimura Hideharu,Sakai Kazuko,Sakai Asao,Sone Takashi,Horiike Atsushi,Koizumi Fumiaki,Kasahara Kazuo,Ohira Tatsuo,Ikeda Norihiko,Saijo Nagahiro,Arao Tokuzo,Nishio Kazuto

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Heparan sulphate proteoglycans fine-tune mammalian physiology;Bishop;Nature,2007

2. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights;Coombe;Cell Mol Life Sci,2005

3. Roles of heparan-sulphate glycosaminoglycans in cancer;Sasisekharan;Nat Rev Cancer,2002

4. Structural basis for fibroblast growth factor receptor activation;Mohammadi;Cytokine Growth Factor Rev,2005

5. Role of heparan sulfate in fibroblast growth factor signalling: a structural view;Pellegrini;Curr Opin Struct Biol,2001

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients;Translational Lung Cancer Research;2022-10

2. Circulating Proteoglycans/Glycosaminoglycans as Cancer Biomarkers;The Extracellular Matrix and the Tumor Microenvironment;2022

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

;Lung Cancer: Targets and Therapy;2020-09

4. The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target;RSC Advances;2019

5. Activation Route of the Schistosoma mansoni Cathepsin B1 Drug Target: Structural Map with a Glycosaminoglycan Switch;Structure;2014-12